Efficacy and Safety of Cyclin-Dependent Kinases 4 and 6 Inhibitors in HR+/HER2− Advanced Breast Cancer

PURPOSE: To assess the efficacy and safety of cyclin-dependent kinases 4 and 6 inhibitors (CDKi) combined with endocrine therapy (ET) in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) and compare the efficacy of differ...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Ning, Qin, Tao, Ren, Wei, Yao, Herui, Yu, Yunfang, Hong, Huangming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280088/
https://www.ncbi.nlm.nih.gov/pubmed/32581595
http://dx.doi.org/10.2147/CMAR.S254365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280088/
https://www.ncbi.nlm.nih.gov/pubmed/32581595
http://dx.doi.org/10.2147/CMAR.S254365

Ejemplares similares